These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26381277)

  • 1. Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.
    Declerck P; Farouk-Rezk M; Rudd PM
    Pharm Res; 2016 Feb; 33(2):261-8. PubMed ID: 26381277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical data and regulatory issues of biosimilar products.
    Stevenson JG
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The process defines the product: what really matters in biosimilar design and production?
    Vulto AG; Jaquez OA
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific factors and current issues in biosimilar studies.
    Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
    J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explaining biosimilars and how reverse engineering plays a critical role in their development.
    Bellinvia S; Edwards CJ
    Expert Opin Drug Discov; 2020 Nov; 15(11):1283-1289. PubMed ID: 32717155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.
    Vezér B; Buzás Z; Sebeszta M; Zrubka Z
    Curr Med Res Opin; 2016 May; 32(5):829-34. PubMed ID: 26808864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biosimilars versus original biologics. Similarities and differences from development to approval].
    Windisch J
    Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the glycosylation aspects of biosimilarity.
    Hajba L; Szekrényes Á; Borza B; Guttman A
    Drug Discov Today; 2018 Mar; 23(3):616-625. PubMed ID: 29337201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drift, evolution, and divergence in biologics and biosimilars manufacturing.
    Ramanan S; Grampp G
    BioDrugs; 2014 Aug; 28(4):363-72. PubMed ID: 24567263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
    Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
    BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host Cell Proteins: The Hidden Side of Biosimilarity Assessment.
    Mihara K; Ito Y; Hatano Y; Komurasaki Y; Sugimura A; Jones M; Liu H; Mai S; Lara-Velasco O; Bai L; Ketkar A; Adams M; Hirato T; Ionescu R
    J Pharm Sci; 2015 Dec; 104(12):3991-3996. PubMed ID: 26367379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.